Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13584425 | 0.83 | KMT2A (0.46) | HPGDL3MBTL1KMT2ACA1CA2 | |
| Hydrochloric Acid SCHEMBL13584530 | 0.82 | KMT2A (0.45) | HPGDL3MBTL1KMT2ACA1CA2 | |
| SCHEMBL13562878 | 0.81 | PPIB (0.41) | TSHRCA1CA2EPHX2NR1H4 | |
| SCHEMBL14868712 | 0.81 | MEN1 (0.47) | HPGDKMT2A | |
| SCHEMBL13563661 | 0.79 | NPC1 (0.34) | TSHRL3MBTL1KMT2ACA1CA2 | |
| SCHEMBL13563558 | 0.78 | ALDH1A1 (0.53) | HPGDL3MBTL1KMT2AEPHX2NR1H4 | |
| SCHEMBL13562843 | 0.76 | KMT2A (0.34) | TSHRL3MBTL1KMT2AEPHX2NR1H4 | |
| SCHEMBL14868385 | 0.75 | ERCC1 (0.48) | TSHRCA1CA2 | |
| SCHEMBL14872575 | 0.75 | CAPN1 (0.32) | — | |
| SCHEMBL14868596 | 0.75 | GRM5 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2432761-A1 | TREATMENT OF MUSCLE DISEASE CHARACTERIZED BY INSULIN RESISTANCE | Ottawa Hospital Research Institute (CA) | 2012-03-28 | — | — | EP | disclosed |
| WO-2010132982-A1 | TREATMENT OF MUSCLE DISEASE CHARACTERIZED BY INSULIN RESISTANCE | OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) | 2010-11-25 | — | — | WO | disclosed |